cyrilzakka/clinical-trials huggingface dataset:
Interactive Oral Health Educational Program for Children With Intellectual Disability and Their Caregivers

Conducting a research with an interactive oral health educational program and assessing knowledge of caregivers using a questionnaire will help in collecting information about the oral health educational program for children with intellectual disability and the extent of knowledge of care givers in Egypt. This will aid in identifying the knowledge gap, interest, attitude, and practice challenges regarding the children with intellectual disability.

For all children, oral health is a crucial component of overall health, but it is even more crucial for kids with particular medical requirements. Despite the high prevalence of dental disorders among them, people with disabilities or illnesses receive less oral treatment than the general population. According to reports, the largest unmet health need among disabled individuals is dental care. The general health and well-being of the body are closely linked to oral health. The quality of life is enhanced by good dental health. Mentally disabled patients have worse oral health than their normal counterparts, which makes it harder for them to use the oral cavity for activities like eating, swallowing, speaking, chewing, and drooling. This leads to malocclusion, compromised appearance, and poor overall health. Educating parents, guardians, and other caregivers on the causes and self-care prevention of dental disease is a critical part in lowering the caries/gingivitis rate among these children globally. Because of the insufficiency of oral health programs offered in institutions or schools for these particular children, parents and care givers usually have little knowledge about mouth health. they do not understand the significance of dental health, and the educational resources that are accessible to them are frequently insufficient and out-of-date

Eligibility Criteria:
Inclusion Criteria:

* children with intellectual disability
* care givers
* IQ(mild)50-69
* IQ(moderate) 35-49

Exclusion Criteria:

* IQ(severe) 20-34
* refusal to get enrolled in the study.
Use of Probiotic Yogurt in Obese Women

This study aimed to examine the effects of using probiotic yogurt on body components (body weight, height, etc.) and digestive system (distention, gas, etc.) in obesity (obese women), which is an important public health problem all over the world.

Obesity is an important public health problem worldwide and is associated with non-communicable diseases such as Type 2 Diabetes, hypertension, coronary heart disease, hyperlipidemia, non-alcoholic fatty liver, some neoplasms, and infertility disease.However, it is supported by the literature that nutrition and obesity cause microbial dysbiosis.

In this study, it was aimed to use probiotics and yogurt with the thought that nutrition can manipulate the microbiota.

It was aimed to investigate the effects of probiotic yogurt consumption on anthropometric measurements, metabolic parameters, and gastrointestinal symptoms in obese women (25-45 years old) with the prospective method.

The study was carried out in patients who were diagnosed with obesity by the doctor, consulted the Dietitian, and accepted + signed the voluntary consent form.

Total data and measurements were followed and recorded by the same Dietitian. Compliance with medical nutrition therapy, recording of scales were followed weekly.Patients diagnosed with COVID-19 during the study were excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* Female patients aged 25-45 years, with a BMI of 27-35 kg/m2 diagnosed as obese by the doctor
* Female patients without a chronic disease
* Female patients between the ages of 25-45 with regular menstrual cycles,
* Female patients between the ages of 25-45 who are not pregnant or lactating
* Female patients who do not use drugs, herbal products, etc. nutritional supplements.

Exclusion Criteria:

* Patients with BMI≥ 36 kg/m2
* Patients with diabetes, gastrointestinal diseases, CRF, etc.
* Women in pregnancy and lactation period,
* Male patients
* Weight loss medicine etc. patients with drug use
* Patients who use antibiotics
* Patients using probiotics, propolis, herbal products, etc.
* Patients with menstrual irregularity
* Female patients who have entered the menopause
Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis

The purpose of this study is:

To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis.

- Population:

50 patients will be selected from both sexes, healthy, between 18 and 65 years with a clinical diagnosis of chronic plaque psoriasis with PASI \<20%, according to the criteria of inclusion and exclusion.


Eligibility Criteria:
Inclusion Criteria:

* Age range: Between 18 and 65
* A patient with chronic plaque psoriasis
* PASI \<20%
* Presence of bilateral lesions with at least 2 cm in diameter and each with some degree of symmetry
* Levels of serum calcium and phosphorus within the normal range of reference or in case of changes, classified as irrelevant by the investigator
* In the case of female patients, agreement or maintenance of safe use of contraception such as barrier (condom, diaphragm), hormonal contraceptives (pills, implants or injections), IUDs, or abstinence (no sex)
* Reading, understanding, agreement and signature of the patient in the Term of Consent.

Exclusion Criteria:

* Gestation (confirmed by urine test indicator)
* Lactation
* History of hypersensitivity to components of medicines
* Psoriasis with different clinical presentation of the plates
* Clinical picture of psoriasis involving only the scalp, face, groin, armpit and / or other intertriginous area
* Patient requires the use of concomitant medication (topical or systemic) that may alter the course of the disease during the study period
* Use of any systemic treatment for psoriasis within 12 weeks before the start of the study
* Use of systemic corticosteroids within 28 days before the start of the study
* Use of topical corticosteroids or other topical therapies in the areas of assessment within 02 weeks before the start of the study
* Use of phototherapy (UVB / UVA-P) within 04 weeks before the start of the study
* Patients who have participated in another clinical study within 30 days before the start of the study
* Use of any medication or possession of any disease which, in the opinion of the investigator might interfere with the performance or interpretation of the study
* Laboratory tests changed (serum AST and ALT, alkaline phosphatase, urea and creatinine, total bilirubin and fractions)
* Patients with demonstrated hypercalcemia or evidence of toxicity of vitamin D
* Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.


Eligibility Criteria:
Inclusion Criteria:

* CLL according to World Health Organization diagnostic criteria
* Active disease
* No previous treatment
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

* Transformation to aggressive B-cell malignancy (prolymphocytic leukemia, large-cell lymphoma, Hodgkin's lymphoma)
* Other malignancies except for localized skin cancer
* Continuous systemic corticosteroid treatment
* Known infection with hepatitis B or C
Evaluation of the YOFiMeter Glucometer

This evaluation will evaluate a new system from YOFiMeter, known as YOFiLife Blood Glucose Monitoring System with YOFiMeter glucometer. YOFiLife includes a web- based data system known as the Web Portal and smart phone apps for the iPhone and Android. The new YOFiMeter is similar to other glucometers with the exception of built in test cassettes, lancet cassettes with enhanced communications and data reviewing options.

This evaluation will also collect data from a YSI 2300 Stat Plus Glucose Analyzer reference glucometer. The YSI 2300 Stat Plus Glucose Analyzer will be used as the "gold" standard with all results compared to the YSI results.

This is a single evaluation to assess both the Yofimeter system accuracy in the hands of the intended users, as well as other aspects to support lay use, such as labeling assessment and usability. The company is presenting diabetics who monitor their blood glucose with new technological innovations aimed at improving their daily lives (e.g., a unique blood glucose monitor, Web Portal applications and "smart phone" applications).

Each subject selected for the comparison evaluation will perform their own fingerstick and test on their subject device following device instructions. A trained technician will perform a fingerstick on the subject immediately after and perform the test on the same device. Separate results will be recorded by subject and technician. A trained technician will take another blood sample, within as short of a time as practicable, for a glucose assay on the YSI 2300 Stat Plus Glucose Analyzer.

Eligibility Criteria:
Inclusion Criteria:

1. Is the subject currently self-testing for blood glucose levels?
2. Is the subject able to provide legal, written informed consent?
3. Is the subject willing to have fingersticks for blood glucose determination?
4. Does the subject show an ability and willingness to follow directions of the Investigator and staff?
5. Is the subject 18 years of age or older?
6. Does the subject have a hematocrit value in the range of 20-60?

Exclusion Criteria:

1. Does the subject demonstrate a lack of compliance as determined by the Principal or Lead Site Investigator and/or staff?
2. Is the subject currently participating in another clinical study of an investigational device or drug?
3. Is the subject unwilling or unable to provide concurrent blood glucose level determinations with the YOFiMeter whenever blood glucose levels are determined at the Investigator's site?
4. Is the subject, or a family member, employed by a company that develops or markets blood glucose level determining devices?
5. Does the subject have any other condition or finding, which in the opinion of the investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol?
6. Is the subject unwilling or unable to provide Informed Consent (IC)?
Measurement of Circulating Cell-free DNA (cfDNA) for Diagnosis and Prognosis of Various Diseases and Evaluation of Tissue Damage

To characterize the changes in circulating cell-free DNA (cfDNA) levels during cardiopulmonary bypass (CPB) and to access their association with outcomes compared to standard scores.

In a prospective study, the investigators enrolled seventy-one consecutive patients undergoing non-emergent coronary artery bypass grafting. Blood was drawn at baseline, after 20 and 40 minutes on CPB, after cross-clamp removal, and 30 minutes after chest closure. cfDNA was measured in sera by fluorescent method.

The investigators hypothesize that cfDNA measured by will reflect the magnitude of inflammation induced by CPB. Thus, these measurements could serve for the real-time prognosis of patients undergoing cardiac surgery. The investigators correlate cFDNA to laboratories and clinical outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Elective coronary artery bypass grafting surgery

Exclusion Criteria:

* Age \< 18
* Non elective surgery
* other than CABG surgery
* Redo CABG
Thermography of the Foot With Plantar Orthosis Liners

Objetive: To analyze the thermal effects of the types of liners used in the manufacture of the foot orthoses, as well as to establish the thermal differences among them.

Design: Quantitative, experimental, longitudinal and prospective study. Subjects: 47 individuals selected randomly, over 20 years of age Methods: 4 types of liner were studied: natural skin, synthetic leather, perforated E.V.A and E.V.A. without perforation.


Eligibility Criteria:
Inclusion Criteria:

People wearing sanitary footwear. 20-35 years Not having smoked or taken alcohol or exciting drinks before evaluation Without cream on the sking and not being exposed to UV rays.

Exclusion Criteria:

young or old people with respect to the age of study smokers or drinkers
Catheter Salvage in Intestinal Failure Patients

This is an observational study evaluating a catheter salvage strategy in relation to catheter-related bloodstream infections in patients with chronic intestinal failure dependent on home parenteral support. The study is confined to the period 2002 to 2016.

In chronic intestinal failure patients receiving home parenteral support (HPS), catheter-related bloodstream infections (CRBSIs) frequently results in replacement of their tunneled central venous catheters (CVCs) which may lead to future loss of central venous access.

This observational study investigates the consequences of a catheter-salvage-strategy related to CRBSIs according to different causative microorganisms, and short- and long-term risk of recurrence of the CRBSI. The study is based on the Copenhagen Intestinal failure database, which is a web-based database with retrospective data collection performed by reviews of medical charts from all adult intestinal failure patients discharged with home parenteral support from the Department of Medical Gastroenterology, Rigshospitalet.

Eligibility Criteria:
Inclusion Criteria:

* chronic intestinal failure dependent on home parenteral support and enrolled in the Copenhagen Intestinal failure database

Exclusion Criteria:

* Never discharged on home parenteral support
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.

Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.

The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.

This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.

Eligibility Criteria:
Inclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

* Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.

For the quantitative surveys:

* Must be a Castleview Hospital patient who receives the BINDeR-Tx model.

Exclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

* Not familiar with the BINDeR-Tx model
* No interaction with the BINDeR-Tx model

For the quantitative surveys:

* Unable to speak and read English
* Subject is unable to provide contact information
Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects

The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, saliva and nasal lavage fluid in normal and asthmatic subjects.

Nitric oxide (NO) is produced by a variety of cells within the respiratory tract, particularly airway epithelial cells, and its increased concentration in asthma is likely to derive from inducible NO synthase (iNOS) expressed in inflamed airways. To evaluate whether an increased bronchial flux of NO (ie, airway wall NO flux \[Jno\] in picoliters per second) produced in the large airways is due to an enzyme overexpression, we administered a relatively selective iNOS inhibitor, aminoguanidine, by nebulization in a double-blind, placebo-controlled manner in asthmatic and healthy subjects and also investigated whether the same concentration of inhibitor has any effect on NO produced in the peripheral lungs (ie, alveolar NO concentration \[Calv\] in parts per billion \[ppb\]) or on the diffusing capacity of NO (Dno) \[in picoliters per second-1 per ppb-1) in the airways. Aminoguanidine administration resulted in a significant reduction in Jno compared with administration of the saline solution control in eight healthy subjects and in eight patients with asthma but caused no significant changes in Calv or in Dno in either group.

Eligibility Criteria:
Inclusion Criteria:

Healthy non-smokers (n=10):

* Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s)
* Normal spirometry
* Able to comprehend and grant a written informed consent

Asthmatic subjects (n=15):

* Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s)
* Clinically stable (steroid-naïve or taking no \> 600 mcg/day of inhaled steroids)
* Able to comprehend and grant a written informed consent

Exclusion Criteria:

* Currently smoking
* Any lung disease other than asthma which may interfere with the study
* Treatment within the last 4 weeks with oral steroids
* Respiratory infection within 4 weeks prior to entry into the trial
* Females who are pregnant or lactating
* History of current or past drug or alcohol abuse
Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.

Alzheimer's disease is the most common cause of dementia and currently has no disease-modifying treatments or simple, accurate diagnostic tests. Amyloid beta builds up in the brain and forms plaques in people with Alzheimer's disease, and the buildup of this protein is found decades before symptoms of dementia begin. A blood test may be able to quickly and inexpensively screen people for Alzheimer's disease clinical trials and eventually diagnose Alzheimer's disease in the clinic.

Eligibility Criteria:
Inclusion Criteria:

1. At least 60 years of age

Exclusion Criteria:

1. Unable to perform one or more activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment or dependent on others due to cognitive impairment.
2. Body weight of \<100 pounds
3. Active infectious disease (e.g., HIV, hepatitis B, hepatitis C)
4. Bleeding disorder
5. Taking an experimental drug for AD
6. Blood donation in the last two months
7. Blood transfusion in the last three months
8. On hospice
Perioperative Respiratory Adverse events_sugammadex

Perioperative respiratory adverse events are common in children. We aimed to evaluate the effect of sugammadex on the incidence of perioperative respiratory adverse events in pediatric patients receiving tonsillectomy


Eligibility Criteria:
Inclusion Criteria:

* Pediatric patients aged 2-6 years who were scheduled for tonsillectomy under general anesthesia were enrolled

Exclusion Criteria:

* a recent history of upper respiratory tract infection within 2 weeks of surgery
* allergic reaction to sugammadex
* renal failure
* liver failure
* arrhythmia
Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women

The purpose of this study is to determine how common oral HPV infections are in college women. The investigators also will find out what risk factors are associated with having oral HPV infections. The investigators hypothesize that approximately 3% of women will have oral HPV, and that HPV will be associated with oral sexual behaviors and with smoking behaviors. Finally, for those women with oral HPV- the investigators will determine whether the infections are persistent (still present) at 3-, 6-, and 12-months after the initial diagnosis.


Eligibility Criteria:
Inclusion Criteria:

* Age \>=18 years
* Female
* Currently enrolled as a college student

Exclusion Criteria:

* Unable to provide an oral rinse sample
* Unable to complete survey
* Unable to provide contact information
* Already completed study.
Cleaner Air for Lower Cardiometabolic Risk

The purpose of this interventional sham-controlled pilot study is to study the effects of using portable air cleaners (PACs) in outpatient adults with prediabetes. The primary aims are to determine the effect PAC's have on glycemic variability and the concentrations of circulating biomarkers of inflammation.


Eligibility Criteria:
Inclusion Criteria:

* Participant is ≥18 years old
* Participant and members of household are reported to be non-smokers (defined as no household members are currently known to smoke cigarettes or use other tobacco products including e-cigarettes)
* Participant is to understand/speak English or Spanish
* Participant can understand study procedures and give informed consent
* Participant has prediabetes, defined as the absence of diabetes and any of the following: fasting plasma glucose 100-125 mg/dL, 2 hour plasma glucose of 140-199 mg/dL after 75 g oral glucose tolerance test, or A1c 5.7- 6.4%.
* Able to wear CGM for 2 two-week periods
* Able to participate in telephone or video conference for home equipment setup if needed
* Able to visit clinic for blood draws before and after the study period
* Do not intend to sleep anywhere outside of primary bedroom for more than 48 consecutive hours or a total of 7 days during the study period.
* Ability to lift, or access to assistance with lifting, 20 lb to set up air filter appliance in bedroom.
* Have not undergone major dietary change (such as change from usual diet to intermittent fasting or caloric restriction) in the past 2 weeks, and do not intend to during the study period

Exclusion Criteria:

* Participants who have diagnosed diabetes, or take antihyperglycemic medications
* Participants with known atherosclerotic disease: coronary artery disease, peripheral artery disease or history of cerebrovascular disease (stroke or Transient Ischemic Attack (TIA), carotid stenosis)
* Participants with known systemic inflammatory conditions (including but not limited to: inflammatory arthritis, vasculitides, inflammatory bowel diseases, cancer within past 5 years, Hashimoto's thyroiditis)
* Participants currently taking any anti-inflammatory medications or medications that target inflammatory cytokines
* Pregnancy: because blood glucose problems during pregnancy require intensive monitoring and lifestyle changes to protect the mother and fetus
* Participants with known or suspected Covid-19 in the prior 30 days
* Participants with post-covid sequelae (a.k.a "Long covid")
* Participants who are already utilizing HEPA filtration (PAC or within HVAC) in bedrooms